Key stats
About Hwabao WP CSI Pharmaceuticals Index ETF Units
Home page
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Primary advisor
Huabao Fund Management Co. Ltd.
ISIN
CNE100006Y96
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
562050 assets under management is 104.64 M CNY. It's fallen 4.44% over the last month.
562050 fund flows account for −3.31 M CNY (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, 562050 doesn't pay dividends to its holders.
562050 expense ratio is 0.60% meaning you'd have to pay 0.60% of your investment to help manage the fund.
562050 follows the CSI Pharmaceutical Index - CNY - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
562050 trades at a premium (0.03%) meaning the ETF is trading at a higher price than the calculated NAV.